Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications (opens in a new tab)

news-medical.net · 2026-10-22

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 1 supported
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

news-medical.net · 2026-10-22

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of six claims matches the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

  • 1 supported
  • 5 not covered
Open claim evidence
3
Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe SEVUSMART Phase Ib study of sevuparin in children with severe malaria has been published in the peer-reviewed journal Nature Communications.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile does not provide journal, publication-status, or peer-review venue metadata. The claim may be true externally, but it is not verifiable from the supplied paper evidence.

Claim 2 of 6Not coveredSEVUSMART evaluated sevuparin as an adjunctive treatment for severe malaria in children and was conducted as an investigator-led study with Imperial College London as sponsor and Professor Kathryn Maitland as principal investigator.View evidenceHide evidence

Why this verdict

The abstract profile supports that sevuparin was evaluated as adjunctive therapy in hospitalized Kenyan and Zambian children with severe malaria in a Phase I trial. However, the profile does not verify the investigator-led framing, Imperial College London sponsorship, or Professor Kathryn Maitland as principal investigator.

1

Study evidence

Maximum tolerated dose (MTD) of sevuparin identified as 3 mg/kg given as three infusions at 0, 8 and 16 hours.

“A Phase I dose-finding trial in Kenyan and Zambian children hospitalised with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 hours post-enrolment) using the continual reassessment method.”
Claim 3 of 6Not coveredThe dose-limiting toxicities were laboratory-defined modest elevations in APTT, with no clinical bleeding complications.View evidenceHide evidence

As stated>2.5 times the upper limit of normal APTT elevations

Why this verdict

The abstract profile supports that dose-limiting toxicity was defined by APTT >95 seconds, approximately 2.5× the upper limit of normal, and that DLTs guided dose de-escalation. It does not verify the characterization as 'modest' elevations or the statement that there were no clinical bleeding complications.

1

Study evidence

Maximum tolerated dose (MTD) of sevuparin identified as 3 mg/kg given as three infusions at 0, 8 and 16 hours.

“A Phase I dose-finding trial in Kenyan and Zambian children hospitalised with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 hours post-enrolment) using the continual reassessment method.”
2

Study evidence

One death occurred during 28-day follow-up (1/23, 4.3%).1/23 (4.3%)

“Children were followed for 28 days. Grade 3 or 4 serious adverse events were recorded.”
Claim 4 of 6Not coveredThe article says 28-day mortality was 4.3 percent (1 of 23 children), compared with an expected mortality risk of at least 10 percent and historical comparator data of 21–34 percent from the SMAART observational study in similar patients.View evidenceHide evidence

As stated4.3 percent; at least 10 percent; 21–34 percent

Why this verdict

The observed 28-day mortality figure, 1/23 or 4.3%, is supported. The claimed expected mortality risk of at least 10% and the SMAART historical comparator range of 21–34% are not present in the supplied abstract-level profile, so the comparative framing is not verifiable here.

1

Study evidence

One death occurred during 28-day follow-up (1/23, 4.3%).1/23 (4.3%)

“Children were followed for 28 days. Grade 3 or 4 serious adverse events were recorded.”
Claim 5 of 6Not coveredThe article emphasizes that the study was an uncontrolled Phase I study without a comparator arm and therefore the results should be interpreted with caution and confirmed in a controlled trial.View evidenceHide evidence

Why this verdict

The profile supports a small Phase I dose-finding design and does not identify a comparator arm; it also notes limited interpretability for secondary or clinical-effect endpoints. However, the supplied abstract profile does not explicitly verify the article's full cautionary statement that results should be interpreted cautiously until confirmed in a controlled trial.

1

Study evidence

Maximum tolerated dose (MTD) of sevuparin identified as 3 mg/kg given as three infusions at 0, 8 and 16 hours.

“A Phase I dose-finding trial in Kenyan and Zambian children hospitalised with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 hours post-enrolment) using the continual reassessment method.”
2

Study evidence

The trial prespecified and collected secondary endpoints of lactate clearance, parasite half-life, and APTT at 24 hours; the abstract does not report corresponding outcome data or effect estimates.

“Secondary endpoints were lactate clearance, parasite half-life, and APTT at 24 hours.”
Claim 6 of 6SupportedThe study enrolled 23 children with severe malaria in Kenya and Zambia and identified a maximum tolerated dose of 3 mg/kg per infusion.View evidenceHide evidence

As stated23 children; 3 mg/kg per infusion

Why this verdict

The profile reports 23 children enrolled and identifies the final/maximum tolerated dose as 3 mg/kg, with sevuparin given as three infusions at 0, 8, and 16 hours. The MTD finding is supported by the Phase I CRM dose-finding abstract evidence.

1

Study evidence

Maximum tolerated dose (MTD) of sevuparin identified as 3 mg/kg given as three infusions at 0, 8 and 16 hours.

“A Phase I dose-finding trial in Kenyan and Zambian children hospitalised with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 hours post-enrolment) using the continual reassessment method.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The trial enrolled 23 children, with 20 included in the primary analysis.

    The story reports 23 enrolled but does not reflect the abstract-profile detail that only 20 children were included in the primary analysis.

    From Phase I continual reassessment method (CRM) dose-escalation/de-escalation trial

  • Secondary endpoints included lactate clearance, parasite half-life, and APTT at 24 hours, but the abstract profile does not report numerical results for these endpoints.

    The story does not discuss these prespecified secondary endpoints or the limitation that their results are not detailed in the abstract-level evidence.

    From Phase I dose-finding trial (continual reassessment method)

  • Small sample size limits precision of MTD and safety estimates.

    Although the story states that 23 children were enrolled, its listed caveats focus on the lack of a comparator and need for controlled confirmation, not the paper-profile limitation that the small Phase I sample limits precision.

    From Phase I continual reassessment method (CRM) dose-escalation/de-escalation trial; Phase I dose-finding safety follow-up

4 things the story did carry across
  • Phase I CRM dose-finding trial of adjunctive sevuparin in hospitalized children with severe malaria in Kenya and Zambia.
  • Maximum tolerated dose was identified as 3 mg/kg, given as three infusions at 0, 8, and 16 hours.
  • Dose-limiting toxicity was defined as APTT >95 seconds, about 2.5× the upper limit of normal, and DLTs at higher doses led to de-escalation and final dose selection.
  • Phase I exploratory endpoints and lack of detailed secondary-endpoint results limit inference about pharmacodynamic or clinical effects.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine the maximum tolerated dose (MTD) of adjunctive sevuparin in hospitalized African children with severe malaria using a Phase I continual reassessment method (CRM) dose-escalation/de-escalation design.Phase I continual reassessment method (CRM) dose-escalation/de-escalation trialExpand

In plain English

Phase I continual reassessment method (CRM) dose-finding trial of adjunctive sevuparin in Kenyan and Zambian children hospitalized with severe malaria identified a maximum tolerated dose (MTD) of 3 mg/kg given as three intravenous infusions at 0, 8 and 16 hours. Safety was assessed by dose-limiting toxicity (DLT) defined as activated partial thromboplastin time (APTT) >95 seconds (≈2.5× ULN) across planned doses of 1.5–6 mg/kg; 23 children were enrolled (20 in the primary analysis). Dose escalation reached 6 mg/kg when 2 DLTs occurred, after which de-escalation observed DLTs at 5 mg/kg and 4 mg/kg, and the final selected dose was 3 mg/kg. Follow-up was 28 days; there was one death (1/23, 4.3%), one readmission, and one grade 3 non-DLT adverse event, all judged unrelated to sevuparin. Secondary endpoints listed included lactate clearance, parasite half-life, and APTT at 24 hours but results for these are not detailed in the abstract.

Key findings

  • Maximum tolerated dose (MTD) of sevuparin identified as 3 mg/kg given as three infusions at 0, 8 and 16 hours.
  • Observed safety events during the trial included 1 death (1/23, 4.3%), 1 readmission, and 1 grade 3 non-DLT adverse event; these events were judged unrelated to sevuparin in the abstract.
“A Phase I dose-finding trial in Kenyan and Zambian children hospitalised with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 hours post-enrolment) using the continual reassessment method.”
What this piece can’t prove
  • Small enrolled sample (23 total; 20 in primary analysis) — typical of Phase I but limits precision for MTD and safety estimates.
  • Abstract does not report detailed results for prespecified secondary endpoints (lactate clearance, parasite half-life, APTT at 24 hours).
  • Abstract provides limited detail on timing and adjudication of DLTs and on individual participant-level outcomes beyond counts reported.
2human in vivoCharacterize short-term safety/tolerability signals beyond the dose-limiting toxicity definition (e.g., serious adverse events, death, readmission) during 28-day follow-up.Phase I dose-finding safety follow-upExpand

In plain English

In a Phase I dose-finding trial of sevuparin in Kenyan and Zambian children hospitalized with severe malaria, 28-day follow-up captured short-term safety outcomes: 1 death (1/23, 4.3%), 1 readmission, and 1 grade 3 non-DLT adverse event. All reported events were judged unrelated to sevuparin in the abstract.

Key findings

  • One death occurred during 28-day follow-up (1/23, 4.3%).1/23 (4.3%)
  • One hospital readmission was reported during 28-day follow-up.1/23 (4.3%)
“Children were followed for 28 days. Grade 3 or 4 serious adverse events were recorded.”
What this piece can’t prove
  • Small sample size (23 enrolled; 20 in primary analysis) limits precision of event rate estimates.

2 further details could not be confirmed from the summary.

3human in vivoExplore pharmacodynamic/clinical secondary endpoints potentially consistent with biologic effect (e.g., lactate clearance, parasite half-life, and APTT at 24 hours).Phase I dose-finding trial (continual reassessment method)Expand

In plain English

In this Phase I dose-finding trial of sevuparin in children with severe malaria, the abstract lists lactate clearance, parasite half-life, and APTT at 24 hours as prespecified secondary (exploratory) endpoints collected in the treated cohort; the abstract does not report results or effect estimates for these endpoints.

Key findings

  • The trial prespecified and collected secondary endpoints of lactate clearance, parasite half-life, and APTT at 24 hours; the abstract does not report corresponding outcome data or effect estimates.
“Secondary endpoints were lactate clearance, parasite half-life, and APTT at 24 hours.”
What this piece can’t prove
  • Small Phase I sample size limits any inference about pharmacodynamic or clinical effects.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 11 candidate papers

Candidate

Phase I safety and dose-finding trial of sevuparin in children with severe malaria

Http://isrctn.com/ · 2021 · Crossref

Source (opens in a new tab)
Candidate

Peer Review Report For: SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART) [version 2; peer review: 2 approved, 1 approved with reservations]

2024 · Crossref

Source (opens in a new tab)

And 5 more candidates considered.